The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial
Abstract
Background—: Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure. Methods and Results—: The circulating concentration of GDF-15 was measured at baseline (n=1734) and at 12 months (n=1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT). GDF-15 levels at baseline ranged from 259 to 25 637 ng/L and were abnormally high (>1200 ng/L) in 85% of patients. Higher levels were associated with features of worse heart failure and biomarkers of neurohormonal activation, inflammation, myocyte injury, and renal dysfunction. Baseline GDF-15 levels (per 100 ng/L) were associated with the risks of mortality (hazard ratio, 1.017; 95% confidence interval, 1.014 to 1.019; P <0.001) and first morbid event (hazard ratio, 1.020; 95% confidence interval, 1.017 to 1.023; P <0.001). In a comprehensive multiple-variable Cox regression model that included clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T, GDF-15 remained independently associated with mortality (hazard ratio, 1.007; 95% confidence interval, 1.001 to 1.014; P =0.02) but not first morbid event. At 12 months, the GDF-15 levels had increased by a similar amount in the placebo and valsartan groups ( P =0.94). Increases in GDF-15 over 12 months were independently associated with the risks of future mortality and first morbid event also after adjustment for clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T and their changes. Conclusions—: GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure. GDF-15 levels increase over time, suggesting that GDF-15 reflects a pathophysiological axis that is not completely addressed by the therapies prescribed in Val-HeFT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationThe Seattle Heart Failure Model: Prediction of Survival in Heart Failure
Levy, W. C., Mozaffarian, D., Linker, D. T., Sutradhar, S. C., Anker, S. D., Cropp, A. B., Anand, I., Maggioni, A., Burton, P., Sullivan, M. D., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.584102 · Cited by 2,021
Self-citationBraunwald, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800239 · Cited by 1,257
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily
Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11514 · Cited by 1,177
B-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
Predictors of mortality and morbidity in patients with chronic heart failure
Pocock, S. J., Wang, D., Pfeffer, M. A., Yusuf, S., McMurray, J. J. V., Swedberg, K. B., Östergren, J., Michelson, E. L., Pieper, K. S., & Granger, C. B. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi555 · Cited by 973
Anand, I. S., Fisher, L. D., Chiang, Y.-T., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 864
Self-citationMcMurray, J. J., & Pfeffer, M. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66621-4 · Cited by 831
Latini, R., Masson, S., Anand, I. S., Missov, E., Carlson, M., Vago, T., Angelici, L., Barlera, S., Parrinello, G., Maggioni, A. P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.655076 · Cited by 709
Self-citationKempf, T., Eden, M., Strelau, J., Naguib, M., Willenbockel, C., Tongers, J., Heineke, J., Kotlarz, D., Xu, J., Molkentin, J. D., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000202805.73038.48 · Cited by 651
Self-citationXu, J., Kimball, T. R., Lorenz, J. N., Brown, D. A., Bauskin, A. R., Klevitsky, R., Hewett, T. E., Breit, S. N., & Molkentin, J. D. (2006) · Circulation Research · doi:10.1161/01.res.0000202804.84885.d0 · Cited by 506
Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure
Kempf, T., von Haehling, S., Peter, T., Allhoff, T., Cicoira, M., Doehner, W., Ponikowski, P., Filippatos, G. S., Rozentryt, P., Drexler, H., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.091 · Cited by 491
Self-citationC-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan
Anand, I. S., Latini, R., Florea, V. G., Kuskowski, M. A., Rector, T., Masson, S., Signorini, S., Mocarelli, P., Hester, A., Glazer, R., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.508465 · Cited by 456
Self-citationWollert, K. C., Kempf, T., Peter, T., Olofsson, S., James, S., Johnston, N., Lindahl, B., Horn-Wichmann, R., Brabant, G., Simoons, M. L., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.650846 · Cited by 379
Self-citationSTRESS signaling pathways that modulate cardiac myocyte apoptosis
BAINES, C., & MOLKENTIN, J. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.11.004 · Cited by 333
Hsiao, E. C., Koniaris, L. G., Zimmers-Koniaris, T., Sebald, S. M., Huynh, T. V., & Lee, S.-J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.10.3742-3751.2000 · Cited by 302
Anand, I. S., Kuskowski, M. A., Rector, T. S., Florea, V. G., Glazer, R. D., Hester, A., Chiang, Y. T., Aknay, N., Maggioni, A. P., Opasich, C., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.512988 · Cited by 287
Self-citationKempf, T., Horn-Wichmann, R., Brabant, G., Peter, T., Allhoff, T., Klein, G., Drexler, H., Johnston, N., Wallentin, L., & Wollert, K. C. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076828 · Cited by 285
Self-citationLind, L., Wallentin, L., Kempf, T., Tapken, H., Quint, A., Lindahl, B., Olofsson, S., Venge, P., Larsson, A., Hulthe, J., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp261 · Cited by 243
Self-citationWollert, K. C., Kempf, T., Lagerqvist, B., Lindahl, B., Olofsson, S., Allhoff, T., Peter, T., Siegbahn, A., Venge, P., Drexler, H., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.697714 · Cited by 232
Self-citationKempf, T., Bjorklund, E., Olofsson, S., Lindahl, B., Allhoff, T., Peter, T., Tongers, J., Wollert, K. C., & Wallentin, L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm465 · Cited by 227
Self-citationSchlittenhardt, D., Schober, A., Strelau, J., Bonaterra, G. A., Schmiedt, W., Unsicker, K., Metz, J., & Kinscherf, R. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0986-3 · Cited by 224
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure
Wong, M., Staszewsky, L., Latini, R., Barlera, S., Glazer, R., Aknay, N., Hester, A., Anand, I., & Cohn, J. N. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.12.053 · Cited by 222
Self-citationBruins, S., Fokkema, M. R., Römer, J. W. P., DeJongste, M. J. L., van der Dijs, F. P. L., van den Ouweland, J. M. W., & Muskiet, F. A. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038752 · Cited by 221
Zimmers, T. A., Jin, X., Hsiao, E. C., McGrath, S. A., Esquela, A. F., & Koniaris, L. G. (2005) · PubMed · Cited by 199
Ding, Q., Mracek, T., Gonzalez-Muniesa, P., Kos, K., Wilding, J., Trayhurn, P., & Bing, C. (2009) · Endocrinology · doi:10.1210/en.2008-0952 · Cited by 193
Frank, D., Kuhn, C., Brors, B., Hanselmann, C., Lüdde, M., Katus, H. A., & Frey, N. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.098046 · Cited by 180
Schober, A., Bottner, M. B., Strelau, J., Kinscherf, R., Bonaterra, G. A., Barth, M., Schilling, L., Fairlie, W. D., Breit, S. N., & Unsicker, K. (2001) · The Journal of Comparative Neurology · doi:10.1002/cne.1333 · Cited by 151
Anand, I. S., Bishu, K. G., Rector, T. S., Ishani, A., Kuskowski, M. A., & Cohn, J. N. (2009) · Circulation · doi:10.1161/circulationaha.109.853648 · Cited by 145
Self-citationKempf, T., Sinning, J., Guba‐Quint, A., Bickel, C., Sinning, C., Wild, P. S., Schnabel, R. B., Lubos, E., Rupprecht, H. J., Münzel, T. F., et al. (2009) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.824870 · Cited by 143
Self-citationAntiangiogenic Activity of the MDM2 Antagonist Nutlin-3
Secchiero, P., Corallini, F., Gonelli, A., Dell’Eva, R., Vitale, M., Capitani, S., Albini, A., & Zauli, G. (2006) · Circulation Research · doi:10.1161/01.res.0000253975.76198.ff · Cited by 125
Molecular regulation of the brain natriuretic peptide gene
LaPointe, M. C. (2005) · Peptides · doi:10.1016/j.peptides.2004.08.028 · Cited by 112
Bermúdez, B., López, S., Pacheco, Y. M., Villar, J. R., Muriana, F. J. G., Hoheisel, J. D., Bauer, A. S., & Abia, R. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn082 · Cited by 85
GDF15 Triggers Homeostatic Proliferation of Acid-Secreting Collecting Duct Cells
Huyen, J. D. V., Cheval, L., Bloch-Faure, M., Bélair, M. F., Heudes, D., Bruneval, P., & Doucet, A. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007070781 · Cited by 84
Foley, P. W. X., Stegemann, B., Ng, K., Ramachandran, S., Proudler, A. J., Frenneaux, M. P., Ng, L. L., & Leyva, F. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp300 · Cited by 52
Frankenstein, L., Remppis, A., Frankenstein, J., Heß, G., Zdunek, D., Gut, S., Slottje, K., Katus, H. A., & Zugck, C. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-009-0027-1 · Cited by 18
Cited by
Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease
Wollert, K. C., Kempf, T., & Wallentin, L. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.255174 · Cited by 559
Self-citationBiomarkers for the diagnosis and management of heart failure
Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10105-w · Cited by 512
Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study
Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., Ho, J. E., Fradley, M. G., Ghorbani, A., Xanthakis, V., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.129437 · Cited by 482
“15 are markedly elevated and correlate with both disease severity and mortality risk.(14,16) Emerging data suggest that GDF-15 concentrations may also be prognostic in unselected populations.”
BackgroundResultAdela, R., & Banerjee, S. K. (2015) · Journal of Diabetes Research · doi:10.1155/2015/490842 · Cited by 474
“Higher GDF-15 levels are associated with adverse outcomes independent of established clinical and biochemical risk factors [40, 65].”
BackgroundBiomarkers and diagnostics in heart failure
Gaggin, H. K., & Januzzi, J. L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.014 · Cited by 423
Metadata
- Authors
- Anand, I. S., Kempf, T., Rector, T. S., Tapken, H., Allhoff, T., Jantzen, F., Kuskowski, M., Cohn, J. N., Drexler, H., & Wollert, K. C.
- Venue
- Circulation
- Published
- 2010-10-05
- Volume
- 122
- Issue
- 14
- Pages
- 1387-1395
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2071101151
- Cited by
- 319
- References
- 38
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.